• Info
  • Significant Ownership

Significant Ownership of Soleus Capital Master Fund, L.P.

Signature - Title
/s/ Guy Levy - Guy Levy/Managing Member
Location
Greenwich, CT
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Soleus Capital Master Fund, L.P..

Notify me when Soleus Capital Master Fund, L.P. files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Soleus Capital Master Fund, L.P.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
THTX THERATECHNOLOGIES INC. Common Stock 10% $13,779,946 4,801,375 SOLEUS CAPITAL MASTER FUND, L.P. 11 Apr 2025
CCCC C4 Therapeutics, Inc Common Stock, par value $0.0001 per share 10% $19,791,153 10,361,860 Soleus Capital Master Fund, L.P. 31 Dec 2025
JSPR JASPER THERAPEUTICS, INC. Common Stock, par value $0.0001 per share 10% $7,068,607 1,494,420 Soleus Capital Management, L.P. 31 Dec 2024
CELC CELCUITY INC. Common Stock 9.9% $42,748,911 3,872,184 Soleus Capital Master Fund, L.P. 31 Dec 2024
EPIX ESSA PHARMA, INC. Common Stock 9.8% $7,415,444 +$3,570,000 4,362,026 +93% SOLEUS CAPITAL MASTER FUND, L.P. 17 Jul 2025
ORGO ORGANOGENESIS HOLDINGS INC. Common Stock, $0.0001 par value per share 7.9% $42,040,854 -$10,520,474 9,985,951 -20% Soleus Capital Master Fund, L.P. 31 Dec 2025
NVCR NOVOCURE LIMITED Ordinary Shares, no par value per share 7.6% $116,443,577 -$15,208,926 8,530,665 -12% Soleus Capital Master Fund, L.P. 31 Dec 2025
VSTM VERASTEM, INC. Common Stock 7.3% $23,421,337 3,350,692 Soleus Capital Management, L.P. 31 Dec 2024
NPCE NEUROPACE, INC. Common Stock, par value $0.001 per share 7% $23,545,122 2,303,828 Soleus Capital Management, L.P. 30 Jun 2025
LUNG PULMONX CORPORATION Common Stock, par value $0.001 per share 6.5% $4,344,113 2,665,100 Soleus Capital Master Fund, L.P. 06 Mar 2026
BDSX BIODESIX INC Common Stock, par value $0.001 per share 6.3% $4,000,000 500,000 Soleus Capital Master Fund, L.P. 12 Jan 2026
IMUX IMMUNIC, INC. Common Stock, par value $0.0001 per share 5.5% $4,143,120 6,792,000 Soleus Capital Master Fund, L.P. 17 Feb 2026
GERN GERON CORPORATION Common Stock, par value $0.001 per share 5.2% $53,143,941 33,008,659 Soleus Capital Master Fund, L.P. 25 Feb 2026
CNTX Context Therapeutics Inc. Common Stock, par value $0.001 per share 5.2% $5,779,442 4,776,398 Soleus Capital Master Fund, L.P. 02 Feb 2026
URGN UROGEN PHARMA LTD. Ordinary Shares, par value NIS 0.01 per share 4.7% $31,114,400 -$1,993,600 2,185,000 -6% Soleus Capital Master Fund, L.P. 30 Jun 2025
PRAX PRAXIS PRECISION MEDICINES, INC. Common Stock, $0.0001 par value per share 4.6% $40,651,514 -$2,144,555 966,740 -5% Soleus Capital Master Fund, L.P. 30 Jun 2025
AXGN AXOGEN, INC. Common Stock, $0.01 par value per share 3.7% $23,369,251 1,446,117 Soleus Capital Master Fund, L.P. 31 Mar 2025
RIGL RIGEL PHARMACEUTICALS, INC. Common Stock, $0.001 par value per share 3.7% $12,327,056 -$8,850,562 658,145 -42% Soleus Capital Master Fund, L.P. 30 Jun 2025
STAA STAAR SURGICAL COMPANY Common Stock, $0.01 par value per share 1% $13,435,000 -$55,429,935 500,000 -80% Soleus Capital Master Fund, L.P. 30 Sep 2025
TERN Terns Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share 0.2% $7,546,951 -$281,348,949 212,710 -97% Soleus Capital Master Fund, L.P. 31 Dec 2025
MURA Mural Oncology plc Ordinary Shares, nominal value $0.01 per share 0% $0 -$2,740,161 0 -100% Soleus Capital Master Fund, L.P. 30 Sep 2025
SRDX SURMODICS, INC. Common Stock, $0.05 par value per share 0% $0 -$22,090,503 0 -100% Soleus Capital Master Fund, L.P. 30 Sep 2025

Schedules 13D/G Reported by Soleus Capital Master Fund, L.P.:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.